<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Obes Metab</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Obes Metab</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1463-1326</journal-id><journal-id journal-id-type="publisher-id">DOM</journal-id><journal-title-group><journal-title>Diabetes, Obesity &#x00026; Metabolism</journal-title></journal-title-group><issn pub-type="ppub">1462-8902</issn><issn pub-type="epub">1463-1326</issn><publisher><publisher-name>Blackwell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29053231</article-id><article-id pub-id-type="pmc">5836949</article-id><article-id pub-id-type="doi">10.1111/dom.13134</article-id><article-id pub-id-type="publisher-id">DOM13134</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Effects of common cold and concomitant administration of nasal decongestant on the pharmacokinetics and pharmacodynamics of nasal glucagon in otherwise healthy participants: <styled-content style="fixed-case">A</styled-content> randomized clinical trial</article-title><alt-title alt-title-type="left-running-head">Guzman et al</alt-title></title-group><contrib-group><contrib id="dom13134-cr-0001" contrib-type="author" corresp="yes"><name><surname>Guzman</surname><given-names>Cristina B.</given-names></name><degrees>MD</degrees><address><email>guzman_cristina_b@lilly.com</email></address><xref ref-type="aff" rid="dom13134-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom13134-cr-0002" contrib-type="author"><name><surname>Dulude</surname><given-names>Helene</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="dom13134-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="dom13134-cr-0003" contrib-type="author"><name><surname>Pich&#x000e9;</surname><given-names>Claude</given-names></name><degrees>MSc</degrees><xref ref-type="aff" rid="dom13134-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="dom13134-cr-0004" contrib-type="author"><name><surname>Rufiange</surname><given-names>Marianne</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="dom13134-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="dom13134-cr-0005" contrib-type="author"><name><surname>Sadoune</surname><given-names>Aziz A.</given-names></name><xref ref-type="aff" rid="dom13134-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="dom13134-cr-0006" contrib-type="author"><name><surname>Rampakakis</surname><given-names>Emmanouil</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="dom13134-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="dom13134-cr-0007" contrib-type="author"><name><surname>Carballo</surname><given-names>Dolores</given-names></name><degrees>MA</degrees><xref ref-type="aff" rid="dom13134-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="dom13134-cr-0008" contrib-type="author"><name><surname>Triest</surname><given-names>Myriam</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="dom13134-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="dom13134-cr-0009" contrib-type="author"><name><surname>Zhang</surname><given-names>Michelle Xiaotian</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="dom13134-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="dom13134-cr-0010" contrib-type="author"><name><surname>Zhang</surname><given-names>Shuyu</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="dom13134-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom13134-cr-0011" contrib-type="author"><name><surname>Tafreshi</surname><given-names>Maryam</given-names></name><xref ref-type="aff" rid="dom13134-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="dom13134-cr-0012" contrib-type="author"><name><surname>Sicard</surname><given-names>Eric</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="dom13134-aff-0003">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="dom13134-aff-0001" content-type="private-address">
<label><sup>1</sup></label>
<institution>Eli Lilly and Company</institution>
<named-content content-type="city">Indianapolis</named-content>
<named-content content-type="country-part">Indiana</named-content>
</aff><aff id="dom13134-aff-0002" content-type="private-address">
<label><sup>2</sup></label>
<institution>Locemia Solutions</institution>
<named-content content-type="city">Montr&#x000e9;al</named-content>
<named-content content-type="country-part">Qu&#x000e9;bec</named-content>
<country country="CA">Canada</country>
</aff><aff id="dom13134-aff-0003" content-type="private-address">
<label><sup>3</sup></label>
<institution>Algorithme Pharma Inc.</institution>
<named-content content-type="city">Montr&#x000e9;al</named-content>
<named-content content-type="country-part">Qu&#x000e9;bec</named-content>
<country country="CA">Canada</country>
</aff><aff id="dom13134-aff-0004" content-type="private-address">
<label><sup>4</sup></label>
<institution>JSS Medical Research</institution>
<named-content content-type="city">Montr&#x000e9;al</named-content>
<named-content content-type="country-part">Qu&#x000e9;bec</named-content>
<country country="CA">Canada</country>
</aff><aff id="dom13134-aff-0005" content-type="private-address">
<label><sup>5</sup></label>
<institution>Eli Lilly Canada Inc.</institution>
<named-content content-type="city">Toronto</named-content>
<named-content content-type="country-part">Ontario</named-content>
<country country="CA">Canada</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Cristina Guzman, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285.<break/>
Email: <email>guzman_cristina_b@lilly.com</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>19</day><month>11</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>3</month><year>2018</year></pub-date><volume>20</volume><issue>3</issue><issue-id pub-id-type="doi">10.1111/dom.2018.20.issue-3</issue-id><fpage>646</fpage><lpage>653</lpage><history><date date-type="received"><day>26</day><month>5</month><year>2017</year></date><date date-type="rev-recd"><day>25</day><month>9</month><year>2017</year></date><date date-type="accepted"><day>14</day><month>10</month><year>2017</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2018 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2017 The Authors. <italic>Diabetes, Obesity and Metabolism</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution&#x02010;NonCommercial&#x02010;NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:DOM-20-646.pdf"/><abstract><sec id="dom13134-sec-0001"><title>Aims</title><p>Nasal glucagon (NG) is a nasally&#x02010;administered glucagon powder, absorbed through the nasal mucosa, designed for treatment of severe hypoglycaemia. This study evaluated the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of NG in otherwise healthy participants with common colds and after recovery from cold symptoms, with and without concomitant nasal decongestant.</p></sec><sec id="dom13134-sec-0002"><title>Materials and Methods</title><p>This was a single&#x02010;centre, open&#x02010;label study. Cohort 1 participants (N&#x02009;=&#x02009;18) received 2 doses of NG: one while experiencing nasal congestion and another after recovery from cold symptoms. Cohort 2 participants (N&#x02009;=&#x02009;18), who also had colds with nasal congestion, received a single dose of NG 2&#x02009;hours after treatment with the decongestant oxymetazoline. Total symptoms score and other safety measures were assessed before and after NG administration.</p></sec><sec id="dom13134-sec-0003"><title>Results</title><p>NG was well tolerated, without serious adverse events. Common adverse events (transient lacrimation, nasal discomfort, rhinorrhea and nausea) were more frequent in both Cohorts 1 and 2 during nasal congestion. Glucagon levels peaked 18&#x02009;minutes post&#x02010;dose and glucose levels peaked 30 to 42&#x02009;minutes post&#x02010;dose in all groups. Nasal congestion, with or without concomitant nasal decongestant, did not significantly affect PK of NG. Although glucose AUECs<sub>0&#x02010;t</sub> was different between Cohort 1 with nasal congestion and Cohort 2, glucose concentrations at 30&#x02009;minutes appeared similar in all groups.</p></sec><sec id="dom13134-sec-0004"><title>Conclusions</title><p>There were no clinically relevant differences in safety or PK/PD of NG associated with nasal congestion or concomitant administration of nasal decongestant, suggesting that NG can be used to treat severe hypoglycaemia in individuals experiencing nasal congestion.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="dom13134-kwd-0001">glucagon</kwd><kwd id="dom13134-kwd-0002">hypoglycaemia</kwd></kwd-group><funding-group><award-group><funding-source>Locemia Solutions, Montr&#x000e9;al, Qu&#x000e9;bec, Canada</funding-source></award-group><award-group><funding-source>Eli Lilly and Company</funding-source></award-group></funding-group><counts><fig-count count="2"/><table-count count="3"/><page-count count="8"/><word-count count="5593"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>dom13134</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>March 2018</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.3.2.2 mode:remove_FC converted:05.03.2018</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="self-citation" id="dom13134-cit-9001">
<string-name>
<surname>Guzman</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Dulude</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Pich&#x000e9;</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Effects of common cold and concomitant administration of nasal decongestant on the pharmacokinetics and pharmacodynamics of nasal glucagon in otherwise healthy participants: A randomized clinical trial</article-title>. <source>Diabetes Obes Metab</source>. <year>2018</year>;20:<fpage>646</fpage>&#x02013;<lpage>653</lpage>. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/dom.13134">https://doi.org/10.1111/dom.13134</ext-link>
<pub-id pub-id-type="pmid">29053231</pub-id></mixed-citation>
</p><fn-group id="dom13134-ntgp-0101"><fn id="dom13134-note-0101"><p>
<bold>Funding information</bold> Funding was provided by Locemia Solutions, Montr&#x000e9;al, Qu&#x000e9;bec, Canada and by Eli Lilly and Company, Indianapolis, Indiana.</p></fn></fn-group></notes></front><body><sec id="dom13134-sec-0005"><label>1</label><title>INTRODUCTION</title><p>Severe hypoglycaemia is an ever&#x02010;present concern among individuals treated with insulin or insulin secretagogues. In 2011, hypoglycaemia was the first&#x02010;listed diagnosis noted in more than 280&#x02009;000 hospital emergency room visits in the USA.<xref rid="dom13134-bib-0001" ref-type="ref">1</xref> In a survey of individuals with type 1 diabetes (T1D), 11.8% reported seizure or loss of consciousness because of hypoglycaemia within the previous 12&#x02009;months.<xref rid="dom13134-bib-0002" ref-type="ref">2</xref> Fear of hypoglycaemia may influence patients towards higher blood glucose, increasing risks of hyperglycaemia&#x02010;associated complications.<xref rid="dom13134-bib-0003" ref-type="ref">3</xref>, <xref rid="dom13134-bib-0004" ref-type="ref">4</xref>
</p><p>Glucagon is an effective treatment for severe hypoglycaemia. Aqueous glucagon is unstable; thus, glucagon emergency kits contain powdered glucagon which must be reconstituted before being administered.<xref rid="dom13134-bib-0005" ref-type="ref">5</xref>, <xref rid="dom13134-bib-0006" ref-type="ref">6</xref> When treating individuals who are disoriented, unconscious, seizing or convulsing in an emergency situation, people without medical training may find the reconstitution process difficult, time&#x02010;consuming and prone to error. Delays, errors, or failure to administer glucagon during severe hypoglycaemia may negatively impact patient outcomes.<xref rid="dom13134-bib-0007" ref-type="ref">7</xref> Recently, a study has shown that reconstituted recombinant glucagon delivered intranasally in euglycaemic individuals is rapidly absorbed into the systemic circulation and acts to increase blood glucose.<xref rid="dom13134-bib-0008" ref-type="ref">8</xref> A form of glucagon that does not require reconstitution could be more beneficial, as it could be administered more quickly.</p><p>Nasal glucagon (NG), a novel drug/device combination product, is being developed for treatment of severe hypoglycaemia. The needle&#x02010;free, ready&#x02010;to&#x02010;use device delivers a dry powdered formulation into the patient's nostril. Administration of injectable glucagon requires several steps, including reconstitution, and is prone to error. In a simulation study, NG administration was faster and provided greater probability of success in delivering the full dose by caregivers (94% vs 13%) and others (93% vs 0%), with fewer errors compared to injectable glucagon.<xref rid="dom13134-bib-0009" ref-type="ref">9</xref>
</p><p>Nasal administration is effective for delivery of medications and vaccines.<xref rid="dom13134-bib-0010" ref-type="ref">10</xref> The human nasal cavity has a volume of 15 to 20&#x02009;mL and a surface area of approximately 150&#x02009;cm<sup>2</sup>. Because of this large surface area and the rich blood supply, medications can be readily absorbed through the nasal mucosa.<xref rid="dom13134-bib-0010" ref-type="ref">10</xref> Most commonly, nasally&#x02010;administered drugs are for the treatment of acute or chronic nasal symptoms (eg, decongestants). However, drugs that act systemically are also administered nasally,<xref rid="dom13134-bib-0010" ref-type="ref">10</xref> including treatments for migraine (eg, zolmitriptan and sumatriptan),<xref rid="dom13134-bib-0010" ref-type="ref">10</xref> pain (eg, fentanyl)<xref rid="dom13134-bib-0010" ref-type="ref">10</xref>, <xref rid="dom13134-bib-0011" ref-type="ref">11</xref> and drug overdose (eg, naloxone).<xref rid="dom13134-bib-0012" ref-type="ref">12</xref> Lipophilic drugs are well absorbed from the nasal cavity and often have pharmacokinetic profiles and bioavailability comparable to intravenously&#x02010;injected drugs.<xref rid="dom13134-bib-0013" ref-type="ref">13</xref>
</p><p>The NG formulation contains the lipophilic excipient dodecylphosphocholine, which helps to enhance absorption. Dodecylphosphocholine contains a choline group, a phosphate group and a saturated aliphatic chain. All 3 moieties are present in phospholipids and lecithins which are ubiquitous in mammalian cell membranes. The synthetic glucagon in the formulation is a single&#x02010;chain, 29&#x02010;amino acid polypeptide identical to the human recombinant DNA&#x02010;derived glucagon used in injectable emergency kits.</p><p>NG is delivered with a single&#x02010;use device, inserted into the patient's nostril. When the plunger on the device is depressed, glucagon powder is propelled into the anterior region of the nasal cavity (Figure <xref rid="dom13134-fig-0001" ref-type="fig">1</xref>).<xref rid="dom13134-bib-0014" ref-type="ref">14</xref> The powder then dissolves and is passively absorbed into the blood stream via the moist membrane of the nasal mucosa without requiring the patient to actively inhale or breathe deeply.</p><fig fig-type="Figure" xml:lang="en" id="dom13134-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Diagram of the nasal passage and sinuses. [For illustrative purposes only.] From Intranasal Drug Administration &#x02014; An Attractive Delivery Route for Some Drugs by Degenhard Marx, Gerallt Williams and Matthias Birkhoff (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.5772/59468">http://dx.doi.org/10.5772/59468</ext-link>). Use of the figure does not assert or imply any connection with, sponsorship or endorsement by the Original Authors and is subject to Creative Commons License 3.0 (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/3.0/legalcode">https://creativecommons.org/licenses/by/3.0/legalcode</ext-link>)</p></caption><graphic id="nlm-graphic-1" xlink:href="DOM-20-646-g001"/></fig><p>NG was well&#x02010;tolerated in preclinical studies<xref rid="dom13134-bib-0015" ref-type="ref">15</xref> and in clinical trials in adult and paediatric patients with T1D.<xref rid="dom13134-bib-0016" ref-type="ref">16</xref>, <xref rid="dom13134-bib-0017" ref-type="ref">17</xref>, <xref rid="dom13134-bib-0018" ref-type="ref">18</xref> In a crossover study of 75 adults with T1D, a 3&#x02010;mg NG dose was noninferior to 1&#x02009;mg injectable glucagon in treating insulin&#x02010;induced hypoglycaemia.<xref rid="dom13134-bib-0017" ref-type="ref">17</xref> NG was also effective in treating naturally&#x02010;occurring hypoglycaemia in home and school settings in children and adolescents, as well as in home and work settings in adults with T1D.<xref rid="dom13134-bib-0018" ref-type="ref">18</xref>, <xref rid="dom13134-bib-0019" ref-type="ref">19</xref>
</p><p>To date, all studies of NG have been conducted in individuals without notable pre&#x02010;existing nasal congestion. However, common cold and associated nasal congestion occur frequently. In one survey, 85% of respondents reported experiencing at least 1 cold within the past year; nasal congestion was among the most common cold symptoms reported.<xref rid="dom13134-bib-0020" ref-type="ref">20</xref> Moreover, some congestion in the nasal passageways is common even in healthy individuals.<xref rid="dom13134-bib-0021" ref-type="ref">21</xref> Therefore, it is important to understand whether the pharmacokinetics (PK) and pharmacodynamics (PD) of NG are affected when nasal congestion is present. Nasal decongestants used for the treatment of cold symptoms may also alter blood glucose levels,<xref rid="dom13134-bib-0022" ref-type="ref">22</xref> as well as affect absorption of nasally&#x02010;administered medications.<xref rid="dom13134-bib-0011" ref-type="ref">11</xref> This study, therefore, enrolled participants with common cold, and compared the effects of NG in participants with nasal congestion and after recovery from cold symptoms, as well as in participants with nasal congestion treated with a decongestant.</p></sec><sec id="dom13134-sec-0006"><label>2</label><title>MATERIAL AND METHODS</title><p>This single&#x02010;centre, open&#x02010;label, repeated&#x02010;measures, parallel&#x02010;design, phase I study examined the safety and PK/PD of a single 3&#x02010;mg dose of NG in otherwise healthy participants with nasal congestion resulting from common cold and after recovering from cold symptoms, as well as in participants with nasal congestion resulting from common cold who had been treated with a nasal decongestant (oxymetazoline, Dristan Long Lasting Nasal Mist 0.05%, Pfizer Consumer Healthcare). The study (<ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">Clinicaltrials.gov</ext-link> identifier NCT02778100) was conducted from March to April of 2013 in Montr&#x000e9;al, Qu&#x000e9;bec according to the Declaration of Helsinki and was approved by the local institutional review board. Informed consent was obtained from all participants.</p><p>All participants had common cold symptoms at study enrollment, as evidenced by a score of 2 or 3 for nasal congestion and/or nasal discharge on the Jackson cold scale,<xref rid="dom13134-bib-0023" ref-type="ref">23</xref> which assesses 8 symptoms of common cold (runny nose, nasal congestion, sneezing, cough, malaise, sore throat, fever/chills and headache) on a scale from 0 (absent) to 3 (severe). Peak nasal inspiratory flow was measured to confirm nasal congestion approximately 1&#x02009;hour before each treatment in Cohort 1 and approximately 30&#x02009;minutes prior to administration of nasal decongestant in Cohort 2. Eligible participants were adult, light&#x02010;, non&#x02010; or ex&#x02010;smokers, 18 to 50&#x02009;years old inclusively, with body mass index &#x02265;18.5 and &#x0003c;30.0&#x02009;kg/m<sup>2</sup>. Aside from cold symptoms, participants were healthy as determined by medical history, physical examination (including vital signs), nasal examination, bilateral anterior rhinoscopy, electrocardiogram (ECG) and clinical laboratory tests, as well as screening for human immunodeficiency virus, hepatitis B, and hepatitis C, and abuse of alcohol and drugs.</p><sec id="dom13134-sec-0007"><label>2.1</label><title>Eligible participants were enrolled into two cohorts.</title><sec id="dom13134-sec-0008"><label>2.1.1</label><title>Cohort 1</title><p>The first 18 participants enrolled were assigned to Cohort 1. These participants received NG treatment twice: first, while suffering from untreated cold symptoms, and again 7 to 28&#x02009;days later (&#x02265;2&#x02009;days after recovery from cold symptoms). Participants were required to have a Jackson cold scale score of 0 before the second NG treatment.</p></sec><sec id="dom13134-sec-0009"><label>2.1.2</label><title>Cohort 2</title><p>The subsequent 18 participants enrolled, also experiencing common cold with nasal congestion, were assigned to Cohort 2. These participants received NG only once. Two hours before NG administration, they were treated with nasal decongestant (oxymetazoline), sprayed twice into each nostril.</p></sec></sec><sec id="dom13134-sec-0010"><label>2.2</label><title>
<styled-content style="fixed-case">NG</styled-content> administration and study procedures</title><p>All participants fasted for 10&#x02009;hours (overnight) before a single 3&#x02010;mg dose of NG was administered in 1 nostril. Participants were closely monitored for safety. Blood samples were collected for measurement of glucagon and glucose concentrations 30 and 15&#x02009;minutes before, just before (time 0) and at 5, 10, 15, 20, 30, 40, 60, 90, 120, 150, and 180&#x02009;minutes after NG administration.</p></sec><sec id="dom13134-sec-0011"><label>2.3</label><title>Analytical methods</title><p>Glucagon levels in plasma samples were analysed using a radioimmunoassay (20&#x02009;pg/mL quantification limit; Millipore Human Glucagon Assay, performed by Northwest Lipid Metabolism and Diabetes Research Laboratories, University of Washington, Seattle, Washington). Plasma glucose was measured using a Synchron&#x000ae; System, which determines GLUCm concentration by an oxygen rate method using a Beckman Coulter Oxygen electrode (Gamma&#x02010;Dynacare Medical Laboratories, St&#x02010;Laurent, Qu&#x000e9;bec, Canada).</p></sec><sec id="dom13134-sec-0012"><label>2.4</label><title>Safety and tolerability</title><p>Safety and tolerability measures included adverse events (AEs) up to 5&#x02009;hours after NG administration, physical examination, nasal examination, bilateral anterior rhinoscopy, standard laboratory evaluations, vital signs and electrocardiogram (ECG). AEs were classified by System Organ Class and Preferred Term using the Medical Dictionary for Regulatory Activities Version 13.1.</p><p>Participants rated their nasal symptoms (runny nose, nasal congestion, nasal itching and sneezing) and non&#x02010;nasal symptoms (watery eyes, itchy eyes, redness of eyes, itching of ears and itching of throat) individually from 0 (absent) to 3 (severe) on the Total Symptom Score questionnaire.<xref rid="dom13134-bib-0024" ref-type="ref">24</xref>, <xref rid="dom13134-bib-0025" ref-type="ref">25</xref> These ratings were collected at approximately 30&#x02009;minutes prior to and at 15, 30, 60 and 180&#x02009;minutes after each glucagon administration.</p></sec><sec id="dom13134-sec-0013"><label>2.5</label><title>Statistical methods</title><p>Three analysis groups were defined: (1) Cohort 1 participants with cold symptoms; (2) Cohort 1 participants without cold symptoms; (3) Cohort 2 participants.</p><p>PK and PD parameters of glucose were derived using non&#x02010;compartmental analysis based on raw concentrations (Area Under the Curve [AUC]<sub>0&#x02010;t</sub> [for PK], Area Under the Effect Curve [AUEC]<sub>0&#x02010;t</sub> [for PD], maximum concentration [C<sub>max</sub>] and time to maximum concentration [T<sub>max</sub>]). Individual concentrations and PK/PD parameters were summarized by analysis group, with descriptive statistics including median for T<sub>max</sub>, and mean and standard deviation (or coefficient of variation) for other parameters.</p><p>Comparison of natural logarithm (ln)&#x02010;transformed PK/PD parameters of glucagon and glucose between analysis group 1 and 2, as well as between analysis group 1 and 3 was conducted using a mixed analysis of variance (ANOVA) model including participant as random effect and presence of cold symptoms or use of decongestant as fixed effects. Predicted geometric means along with 90% confidence intervals were derived. Analyses for PK, PD and safety included all participants who received &#x02265;1 dose of study drug.</p><p>Total nasal and non&#x02010;nasal symptom scores at pre&#x02010;glucagon and various post&#x02010;glucagon administration time&#x02010;points were summarized by analysis group with descriptive statistics including mean and standard error. As a <italic>post&#x02010;hoc</italic> analysis, percentages of participants with a total nasal and non&#x02010;nasal symptom score &#x02265;2 at pre&#x02010;glucagon and various post&#x02010;glucagon administration time&#x02010;points were also summarized by analysis group.</p><p>Change in vital signs from 1 h pre&#x02010; to 45&#x02009;minutes post&#x02010;glucagon administration was summarized by analysis group. Within&#x02010;group difference was assessed using Wilcoxon Signed Rank test. SAS version 9.1 or higher (SAS Institute Inc., Cary, North Carolina) was used. Unless otherwise specified, all tests of statistical significance were evaluated at a nominal level of 0.05 using 2&#x02010;tailed test procedures.</p></sec><sec id="dom13134-sec-0014"><label>2.6</label><title>Power calculations</title><p>To achieve statistical power of &#x02265;80% to demonstrate that nasal decongestant use had no significant impact on the glucose AUEC<sub>0&#x02010;t</sub> (assuming true mean difference is zero) and allowing one standard deviation (1.35&#x02009;hour*mmol/L) as acceptable difference for equivalence, 18 participants per cohort were required; this also provided &#x02265;90% power to demonstrate that nasal congestion had no significant impact on the glucose AUEC<sub>0&#x02010;t</sub> under the same assumption.</p></sec></sec><sec id="dom13134-sec-0015"><label>3</label><title>RESULTS</title><sec id="dom13134-sec-0016"><label>3.1</label><title>Study participants</title><p>A total of 36 participants were enrolled in this study, 18 in each cohort. Baseline demographics were similar for both cohorts (Table <xref rid="dom13134-supitem-0001" ref-type="supplementary-material">S1</xref>). Peak nasal inspiratory air flow measurements confirmed nasal congestion in all participants with colds. Jackson cold scores at baseline ranged from 4 to 15 (Cohort 1 with nasal congestion) and 4 to 13 (Cohort 2). Participants in Cohort 1 were required by protocol to have Jackson cold scores of 0 after recovery from cold symptoms. One participant in Cohort 1 withdrew from the study before receiving a second NG dose (Figure <xref rid="dom13134-supitem-0001" ref-type="supplementary-material">S1</xref>). All other participants completed the trial.</p></sec><sec id="dom13134-sec-0017"><label>3.2</label><title>Glucagon pharmacokinetics</title><sec id="dom13134-sec-0018"><label>3.2.1</label><title>Cohort 1</title><p>Glucagon profiles were similar for Cohort 1 participants while experiencing nasal congestion and after recovery from cold symptoms (Figure <xref rid="dom13134-fig-0002" ref-type="fig">2</xref>A), with glucagon concentrations rising slightly faster when nasal congestion was present. Glucagon concentrations increased substantially above baseline with mean peak concentrations (C<sub>max</sub>) of 1198.4&#x02009;pg/mL (with nasal congestion) and 801.5&#x02009;pg/mL (after recovery from cold symptoms) (Table <xref rid="dom13134-tbl-0001" ref-type="table-wrap">1</xref>). T<sub>max</sub> was 18&#x02009;minutes, both with nasal congestion and after recovery from cold symptoms. The glucagon PK observed during nasal congestion did not show any statistically significant differences compared to that after recovery from cold symptoms in this cohort (Table <xref rid="dom13134-tbl-0002" ref-type="table-wrap">2</xref>).</p><fig fig-type="Figure" xml:lang="en" id="dom13134-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Glucagon and glucose concentrations over time following nasal glucagon administration. A single 3&#x02010;mg dose of nasal glucagon was administered at time 0. Glucagon concentrations are shown in Panel A. Glucose concentrations are shown in Panel B. White circles&#x02009;=&#x02009;Cohort 1 NG with nasal congestion. Black circles&#x02009;=&#x02009;Cohort 1 NG without cold symptoms. White squares&#x02009;=&#x02009;Cohort 2 (NG with nasal congestion, treated with decongestant). Values are given as means (adjusted for baseline concentration)&#x02009;&#x000b1;&#x02009;standard error; NG&#x02009;=&#x02009;nasal glucagon; 1&#x02009;mmol/L&#x02009;=&#x02009;18&#x02009;mg/dL</p></caption><graphic id="nlm-graphic-3" xlink:href="DOM-20-646-g002"/></fig><table-wrap id="dom13134-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Summary of PK parameters of plasma glucagon and PD parameters of plasma glucose</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" align="left" valign="bottom" colspan="1">PK parameters (glucagon)</th><th colspan="2" align="left" valign="bottom" rowspan="1">Cohort 1</th><th align="left" valign="bottom" rowspan="1" colspan="1">Cohort 2</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">NG&#x02009;+&#x02009;Common cold (N&#x02009;=&#x02009;18)</th><th align="left" valign="bottom" rowspan="1" colspan="1">NG&#x02009;+&#x02009;No cold symptoms (N&#x02009;=&#x02009;17)</th><th align="left" valign="bottom" rowspan="1" colspan="1">NG&#x02009;+&#x02009;Common cold&#x02009;+&#x02009;Decongestant (N&#x02009;=&#x02009;18)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">AUC<sub>0&#x02010;t</sub>, h&#x000b7;pg/mL<xref ref-type="fn" rid="dom13134-note-0003">a</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">1198.4 (84.6)</td><td align="left" valign="top" rowspan="1" colspan="1">797.5 (50.1)</td><td align="left" valign="top" rowspan="1" colspan="1">1038.0 (60.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">C<sub>max</sub>, pg/mL<xref ref-type="fn" rid="dom13134-note-0003">a</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">1198.4 (83.0)</td><td align="left" valign="top" rowspan="1" colspan="1">801.5 (68.2)</td><td align="left" valign="top" rowspan="1" colspan="1">868.0 (68.8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">T<sub>max</sub>, minutes<xref ref-type="fn" rid="dom13134-note-0004">b</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">18 (5, 90)</td><td align="left" valign="top" rowspan="1" colspan="1">18 (15, 40)</td><td align="left" valign="top" rowspan="1" colspan="1">18 (10, 60)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PD parameters (glucose)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AUEC<sub>0&#x02010;t</sub>, h&#x000b7;mmol/L<xref ref-type="fn" rid="dom13134-note-0003">a</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">17.0 (16.9)</td><td align="left" valign="top" rowspan="1" colspan="1">16.4 (13.4)</td><td align="left" valign="top" rowspan="1" colspan="1">19.0 (14.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">C<sub>max</sub>, mmol/L<xref ref-type="fn" rid="dom13134-note-0003">a</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">8.0 (22.9)</td><td align="left" valign="top" rowspan="1" colspan="1">7.7 (19.4)</td><td align="left" valign="top" rowspan="1" colspan="1">8.8 (17.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">T<sub>max</sub>, minutes<xref ref-type="fn" rid="dom13134-note-0004">b</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">30 (15, 60)</td><td align="left" valign="top" rowspan="1" colspan="1">36 (20, 60)</td><td align="left" valign="top" rowspan="1" colspan="1">42 (20, 60)</td></tr></tbody></table><table-wrap-foot><fn id="dom13134-note-0002"><p>Abbreviations: AUC<sub>0&#x02010;t</sub>, area under the curve from time zero; AUEC<sub>0&#x02010;t</sub>, area under the effect curve from time zero; C<sub>max</sub>, maximum concentration; CV, coefficient of variation; NG, nasal glucagon; PD, pharmacodynamics; PK, pharmacokinetics; T<sub>max</sub>, time to maximum concentration; for glucose, 1&#x02009;mmol/L&#x02009;=&#x02009;18&#x02009;mg/dL.</p></fn><fn id="dom13134-note-0003"><label>a</label><p>Arithmetic mean (CV%).</p></fn><fn id="dom13134-note-0004"><label>b</label><p>Median (minimum, maximum).</p></fn></table-wrap-foot></table-wrap><table-wrap id="dom13134-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Comparison of plasma glucagon PK parameters and plasma glucose PD parameters</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1" colspan="1">Comparison</th><th colspan="3" align="left" valign="bottom" rowspan="1">Cohort 1 &#x02010; Common cold vs Cohort 2 &#x02010; Common cold&#x02009;+&#x02009;Decongestant</th><th colspan="3" align="left" valign="bottom" rowspan="1">Cohort 1 &#x02010; Common cold vs Cohort 1 &#x02010; No cold symptoms</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">PK parameters (glucagon)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Estimated difference</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic>P</italic> value</th><th align="left" valign="bottom" rowspan="1" colspan="1">90% CI for difference of geometric means of transformed values</th><th align="left" valign="bottom" rowspan="1" colspan="1">Estimated difference</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic>P</italic> value</th><th align="left" valign="bottom" rowspan="1" colspan="1">90% CI for difference of geometric means of transformed values</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">LnAUC<sub>0&#x02010;t</sub> (h&#x000b7;pg/mL)</td><td align="left" valign="top" rowspan="1" colspan="1">0.010</td><td align="left" valign="top" rowspan="1" colspan="1">0.967</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.39, 0.415</td><td align="left" valign="top" rowspan="1" colspan="1">0.230</td><td align="left" valign="top" rowspan="1" colspan="1">0.331</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.165, 0.625</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LnC<sub>max</sub> (pg/mL)</td><td align="left" valign="top" rowspan="1" colspan="1">0.161</td><td align="left" valign="top" rowspan="1" colspan="1">0.552</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.294, 0.617</td><td align="left" valign="top" rowspan="1" colspan="1">0.250</td><td align="left" valign="top" rowspan="1" colspan="1">0.357</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.210, 0.710</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PD parameters (glucose)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">LnAUEC<sub>0&#x02010;t</sub>, h&#x000b7;mmol/L</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.116</td><td align="left" valign="top" rowspan="1" colspan="1">0.023</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.198, &#x02212;0.034</td><td align="left" valign="top" rowspan="1" colspan="1">0.038</td><td align="left" valign="top" rowspan="1" colspan="1">0.132</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.004, 0.079</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">LnC<sub>max</sub>, mmol/L</td><td align="left" valign="top" rowspan="1" colspan="1">0.114</td><td align="left" valign="top" rowspan="1" colspan="1">0.109</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.231, 0.003</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.026</td><td align="left" valign="top" rowspan="1" colspan="1">0.605</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.060, 0.112</td></tr></tbody></table><table-wrap-foot><fn id="dom13134-note-0005"><p>Abbreviations: AUC<sub>0&#x02010;t</sub>, area under the curve from time zero; AUEC<sub>0&#x02010;t</sub>, area under the effect curve from time zero; C<sub>max</sub>, maximum concentration; CI, confidence interval; Ln, natural logarithm.</p></fn></table-wrap-foot></table-wrap></sec><sec id="dom13134-sec-0019"><label>3.2.2</label><title>Cohort 2</title><p>The glucagon profile for Cohort 2 was similar to the 2 profiles for Cohort 1 (Table <xref rid="dom13134-tbl-0001" ref-type="table-wrap">1</xref>), with C<sub>max</sub> and AUC<sub>0&#x02010;t</sub> values for Cohort 2 falling between those for Cohort 1. T<sub>max</sub> was the same as that for both Cohort 1 profiles. There were no statistically significant differences between the profiles for Cohort 1 with nasal congestion and Cohort 1 without nasal congestion or the profile for Cohort 2 (Table <xref rid="dom13134-tbl-0002" ref-type="table-wrap">2</xref>).</p></sec></sec><sec id="dom13134-sec-0020"><label>3.3</label><title>Glucose pharmacodynamics</title><sec id="dom13134-sec-0021"><label>3.3.1</label><title>Cohort 1</title><p>Blood glucose increased within 5&#x02009;minutes after NG administration in participants with nasal congestion and after recovery from cold symptoms (Figure <xref rid="dom13134-fig-0002" ref-type="fig">2</xref>B) with similar profiles. Plasma glucose increased substantially within 30&#x02009;minutes and reached C<sub>max</sub> values of 8.0&#x02009;mmol/L (144&#x02009;mg/dL) during nasal congestion and 7.7&#x02009;mmol/L (139&#x02009;mg/dL) after recovery from cold symptoms, with median T<sub>max</sub> of 30&#x02009;minutes and 36&#x02009;minutes, respectively (Table <xref rid="dom13134-tbl-0001" ref-type="table-wrap">1</xref>).</p></sec><sec id="dom13134-sec-0022"><label>3.3.2</label><title>Cohort 2</title><p>Blood glucose also rose within 5&#x02009;minutes after NG administration in participants with nasal congestion treated with decongestant. C<sub>max</sub> and T<sub>max</sub> for Cohort 2 were 8.8&#x02009;mmol/L (158&#x02009;mg/dL) and 42&#x02009;minutes, respectively. After 30&#x02009;minutes, the glucose concentration for Cohort 2 was 8.1&#x02009;mmol/L (146&#x02009;mg/dL). The glucose profile in Cohort 2 was similar to both of the profiles in Cohort 1 participants during the first 30&#x02009;minutes (Figure <xref rid="dom13134-fig-0002" ref-type="fig">2</xref>B). From 30 to 90&#x02009;minutes after NG administration, glucose concentrations were numerically higher in Cohort 2, resulting in a statistically significantly larger AUEC<sub>0&#x02010;t</sub> (<italic>P</italic>&#x02009;=&#x02009;.023) for Cohort 2 (Table <xref rid="dom13134-tbl-0001" ref-type="table-wrap">1</xref>, Table <xref rid="dom13134-tbl-0002" ref-type="table-wrap">2</xref>, Figure <xref rid="dom13134-fig-0002" ref-type="fig">2</xref>B). Difference in LnAUEC<sub>0&#x02010;t</sub> values was not statistically significant between Cohort 1 with nasal congestion and Cohort 2 after adjusting for baseline glucose concentration (<italic>P</italic>&#x02009;=&#x02009;.503). No other statistically significant differences in PD parameters were observed (Table <xref rid="dom13134-tbl-0002" ref-type="table-wrap">2</xref>).</p></sec></sec><sec id="dom13134-sec-0023"><label>3.4</label><title>Total nasal and non&#x02010;nasal symptom score</title><sec id="dom13134-sec-0024"><label>3.4.1</label><title>Cohort 1</title><p>Before NG administration, total symptom scores were substantially higher for participants experiencing nasal congestion compared to the same participants after recovery from cold symptoms (Figure <xref rid="dom13134-supitem-0001" ref-type="supplementary-material">S2</xref>A). Regardless of whether or not participants were experiencing nasal congestion, mean scores rose 1 to 2 points within 15&#x02009;minutes after glucagon administration, plateaued or declined by 30&#x02009;minutes, and were at or below baseline scores within 3&#x02009;hours.</p><p>While experiencing nasal congestion, all (100%) Cohort 1 participants had total symptom scores &#x02265;2 from 30&#x02009;minutes before glucagon administration until 1&#x02009;hour afterwards (Figure <xref rid="dom13134-supitem-0001" ref-type="supplementary-material">S2</xref>B). A score of &#x02265;2 indicates the presence of &#x02265;2 mild symptoms or &#x02265;1 moderate or severe symptom. After recovery from cold symptoms, no Cohort 1 participants (0%) had scores &#x02265;2 before glucagon administration; 15&#x02009;minutes after administration, 35% had scores &#x02265;2 and the percentage dropped thereafter, reaching 0 within 3&#x02009;hours (Figure <xref rid="dom13134-supitem-0001" ref-type="supplementary-material">S2</xref>B).</p></sec><sec id="dom13134-sec-0025"><label>3.4.2</label><title>Cohort 2</title><p>Scores for Cohort 2 were between the 2 sets of scores for Cohort 1 and followed a similar pattern. The mean score rose within 15&#x02009;minutes after NG administration and fell below baseline scores by 3&#x02009;hours.</p><p>Among Cohort 2 participants, 78% had total symptom scores &#x02265;2 prior to glucagon administration; this percentage was higher at 15 and 30&#x02009;minutes after glucagon administration and returned to baseline 1&#x02009;hour post dose (Figure <xref rid="dom13134-supitem-0001" ref-type="supplementary-material">S2</xref>B).</p></sec></sec><sec id="dom13134-sec-0026"><label>3.5</label><title>Adverse events</title><p>No serious AEs were reported during this study (Table <xref rid="dom13134-tbl-0003" ref-type="table-wrap">3</xref>). All 36 study participants (100%) experienced &#x02265;1 AE, mostly mild or moderate in severity. Four severe AEs were observed in Cohort 1 participants experiencing nasal congestion: nasal congestion (1 participant) and rhinorrhea (3 participants). After recovery from cold symptoms, participants experienced no severe AEs following NG administration. Three severe AEs were observed in Cohort 2 (congestion treated with decongestant): increased lacrimation (1 participant) and nausea (2 participants). The most consistently observed AE was increased lacrimation, a transient increase in tearing most likely explained by the nasal route of administration. AEs, especially those associated with common cold, were considerably more frequent in Cohort 1 participants experiencing nasal congestion compared with participants after recovery from cold symptoms, or with participants in Cohort 2. Other adverse events which are well known glucagon side effects, such as nausea and vomiting, were also reported.</p><table-wrap id="dom13134-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>Most commonly reported adverse events by system organ class</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" align="left" valign="bottom" colspan="1"/><th colspan="2" align="left" valign="bottom" rowspan="1">Cohort 1</th><th style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1" colspan="1">Cohort 2</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Common cold (n&#x02009;=&#x02009;18)</th><th align="left" valign="bottom" rowspan="1" colspan="1">No cold symptoms (n&#x02009;=&#x02009;17)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Common cold&#x02009;+&#x02009;Decongestant (n&#x02009;=&#x02009;18)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Total AEs reported, n</td><td align="left" valign="top" rowspan="1" colspan="1">112</td><td align="left" valign="top" rowspan="1" colspan="1">64</td><td align="left" valign="top" rowspan="1" colspan="1">113</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Patients with &#x02265;1 AE, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">18 (100)</td><td align="left" valign="top" rowspan="1" colspan="1">17 (100)</td><td align="left" valign="top" rowspan="1" colspan="1">18 (100)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Patients with &#x02265;1 treatment&#x02010;related AE, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">18 (100)</td><td align="left" valign="top" rowspan="1" colspan="1">17 (100)</td><td align="left" valign="top" rowspan="1" colspan="1">18 (100)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Serious AEs reported, n</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>AEs by system organ class</bold>
<break/>
Preferred term, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">n (%)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<bold>Ocular</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Increased lacrimation</td><td align="left" valign="top" rowspan="1" colspan="1">13 (72.2)</td><td align="left" valign="top" rowspan="1" colspan="1">12 (70.6)</td><td align="left" valign="top" rowspan="1" colspan="1">12 (66.7)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Ocular hyperaemia</td><td align="left" valign="top" rowspan="1" colspan="1">7 (38.9)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (41.2)</td><td align="left" valign="top" rowspan="1" colspan="1">8 (44.4)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Eye pruritus</td><td align="left" valign="top" rowspan="1" colspan="1">5 (27.8)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">5 (27.8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Respiratory</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Nasal discomfort</td><td align="left" valign="top" rowspan="1" colspan="1">12 (66.7)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (41.2)</td><td align="left" valign="top" rowspan="1" colspan="1">15 (83.3)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Rhinorrhea</td><td align="left" valign="top" rowspan="1" colspan="1">10 (55.6)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (29.4)</td><td align="left" valign="top" rowspan="1" colspan="1">14 (77.8)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Nasal congestion</td><td align="left" valign="top" rowspan="1" colspan="1">4 (22.2)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (17.6)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (22.2)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Sneezing</td><td align="left" valign="top" rowspan="1" colspan="1">5 (27.8)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (17.6)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (16.7)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<bold>Nervous system</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Dizziness</td><td align="left" valign="top" rowspan="1" colspan="1">4 (22.2)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (29.4)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (27.8)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Headache</td><td align="left" valign="top" rowspan="1" colspan="1">4 (22.2)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (17.6)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (27.8)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Somnolence</td><td align="left" valign="top" rowspan="1" colspan="1">6 (33.3)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (17.6)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (5.6)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<bold>Gastrointestinal</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Nausea</td><td align="left" valign="top" rowspan="1" colspan="1">8 (44.4)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (11.8)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (38.9)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Vomiting</td><td align="left" valign="top" rowspan="1" colspan="1">1 (5.6)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">5 (27.8)</td></tr></tbody></table><table-wrap-foot><fn id="dom13134-note-0006"><p>Abbreviation: AE, adverse event.</p></fn></table-wrap-foot></table-wrap></sec><sec id="dom13134-sec-0027"><label>3.6</label><title>Other safety measures</title><p>Blood pressure (BP) and pulse were measured 1&#x02009;hour before NG administration and 45&#x02009;minutes afterwards. Statistically&#x02010;significant increases in BP were observed in each treatment group except for diastolic BP in Cohort 1 participants with cold symptoms, and were more pronounced with the use of nasal decongestant. There were no significant changes in pulse (Table <xref rid="dom13134-supitem-0001" ref-type="supplementary-material">S2</xref>). Results of physical examination, nasal examination, bilateral anterior rhinoscopy, clinical pathology and ECG did not suggest treatment&#x02010;related safety concerns.</p></sec></sec><sec id="dom13134-sec-0028"><label>4</label><title>DISCUSSION</title><p>NG was effective in rapidly raising blood glucose. Comparable PD was observed when participants had nasal congestion and after recovery from cold symptoms (Cohort 1). Participants with nasal congestion treated with decongestant (Cohort 2) had statistically significantly higher glucose AUEC<sub>0&#x02010;t</sub> than participants in Cohort 1 with untreated nasal congestion. This could be an effect of the decongestant used, as oxymetazoline does alter blood glucose.<xref rid="dom13134-bib-0026" ref-type="ref">26</xref> Other PD parameters, including C<sub>max</sub>, were not statistically significantly different, regardless of the presence or absence of nasal congestion or administration of nasal decongestant. As seen in Figure <xref rid="dom13134-fig-0002" ref-type="fig">2</xref>B, glucose responses at 30&#x02009;minutes were similar among the Cohorts. The comparable glucose responses within the first 30&#x02009;minutes are the most important to consider because a rapid and reliable rise in plasma glucose is the most clinically&#x02010;meaningful attribute for rescue treatment during severe hypoglycaemia.</p><p>No significant differences in PK parameters were observed in this study. Prior data with injected glucagon showed that small variations in glucagon pharmacokinetics would not be expected to significantly impact either the glucose response or the safety profile as intravenous administration of a 2&#x02010;mg dose of glucagon did not increase blood glucose concentrations more than a 0.25&#x02010;mg dose of glucagon, indicating clear saturation of the PD response (maximal effective concentration of glucagon exceeded even at the lower dose).<xref rid="dom13134-bib-0007" ref-type="ref">7</xref> Although lower doses of glucagon are being investigated to maintain euglycaemia and avoid hypoglycaemia when used in the artificial pancreas,<xref rid="dom13134-bib-0027" ref-type="ref">27</xref> a supratherapeutic dose that maximizes the glucose response is desirable in the case of severe hypoglycaemia rescue. For NG, 3&#x02009;mg is the dose identified as non&#x02010;inferior to injectable glucagon in glucose response.<xref rid="dom13134-bib-0017" ref-type="ref">17</xref>
</p><p>Comparable results were seen with NG in patients with type 1 or type 2 diabetes who were treated with single or repeated 3&#x02010;mg doses of NG in a randomized sequence. Repeated doses of NG (doubling the NG dose) resulted in higher glucagon concentrations, but glucose responses resembled those seen with a single dose.<xref rid="dom13134-bib-0028" ref-type="ref">28</xref> Although repeat dosing resulted in greater systemic glucagon exposure, it did not result in a clinically&#x02010;meaningful increase in glucose response. All NG treatments were generally well&#x02010;tolerated. Many observed AEs were related to local tolerability, probably explained by the route of administration. Other AEs are well&#x02010;known effects of glucagon administration. These events include nausea, vomiting and increased blood pressure.<xref rid="dom13134-bib-0006" ref-type="ref">6</xref> Increased pulse rate is also observed generally with glucagon administration; however, we did not see a significant change in pulse rate in this study. Administration of oxymetazoline, which acts as a vasoconstrictor,<xref rid="dom13134-bib-0022" ref-type="ref">22</xref> may also have contributed to the rise in blood pressure, which was more pronounced in participants treated with a decongestant.</p><p>Despite the presence of cold symptoms in this study, these PK, PD and safety results are similar to those observed in a study of glucagon in individuals with T1D who were not experiencing nasal congestion,<xref rid="dom13134-bib-0017" ref-type="ref">17</xref> indicating that NG PK/PD were not significantly altered by nasal congestion, with or without use of a nasal decongestant. This is in contrast to a study of nasally&#x02010;administered fentanyl, where absorption was somewhat compromised and T<sub>max</sub> was delayed by oxymetazoline administration.<xref rid="dom13134-bib-0011" ref-type="ref">11</xref>
</p><p>Strengths of the study include having participants in Cohort 1 serve as their own controls, and the use of a single study centre, which ensured consistency. One potential limitation was the use of a single nasal decongestant, although we selected a decongestant that is among the most commonly used.</p><p>In summary, there were no clinically relevant differences in safety or PK/PD of NG associated with nasal congestion due to common cold or concomitant administration of nasal decongestant. Although there were modest differences in total glucose excursions, the onset of glucose response and the glucose excursion observed in the first 30&#x02009;minutes were similar across the 3 groups. Glucagon and glucose levels increased rapidly after treatment, peaking at 18&#x02009;minutes post dose (glucagon) and 30 to 42&#x02009;minutes post dose (glucose) in all groups. These results indicate that a 3&#x02010;mg dose of NG can be used to treat episodes of severe hypoglycaemia in individuals experiencing nasal congestion.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="dom13134-supitem-0001"><caption><p>
<bold>Table S1.</bold> Demographics and baseline characteristics of participants</p><p>
<bold>Table S2.</bold> Blood Pressure and Pulse Rate</p><p>
<bold>Figure S1.</bold> Participant flow diagram.</p><p>
<bold>Figure S2.</bold> Total symptoms scores: scores over time and percentage of participants with scores &#x02265;2 by time.</p></caption><media xlink:href="DOM-20-646-s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="dom13134-sec-0029"><title>ACKNOWLEDGMENTS</title><p>The participation of the people in the study is gratefully acknowledged.</p><p>Assistance with early drafts of this manuscript was provided by David Segarnick, PhD, Chief Medical Officer, MedEvoke (a division of Medisys Health Communication), High Bridge, New Jersey, and was funded by Locemia Solutions, Montr&#x000e9;al, Qu&#x000e9;bec, Canada. Medical writing support for later drafts of this manuscript was provided by Jennie G. Jacobson, PhD, of Eli Lilly and Company, Indianapolis, Indiana.</p><p>Parts of this study have been presented at the 76th Annual Scientific Sessions of the American Diabetes Association, June 10, 2016, and at the 10th International Conference on Advanced Technologies and Treatments for Diabetes, February 15, 2017.</p><sec id="dom13134-sec-0030" sec-type="COI-statement"><title>Conflict of interest</title><p>E. S. is a consultant for Algorithme Pharma Inc. M. R. and A. A. S. are employees of Algorithme Pharma Inc. H. D., M. Tr., C. P. and D. C. are employees and stockholders of Locemia Solutions, which funded the study. M. Ta. and E. R. are employees of JSS Medical Research. M. Z. is an employee of and stockholder in Eli Lilly Canada. C. B. G. and S. Z. are employees of and stockholders in Eli Lilly and Company. Algorithme Pharma Inc. and JSS Medical Research was under contract with Locemia Solutions to perform different portions of this study. The authors report no other conflicts of interest.</p></sec><sec id="dom13134-sec-0031"><title>Author contributions</title><p>C. P., E. S., M. R., M. Tr., E. R. and D. C. designed the study. E. S., M. R., M. Tr., H. D. and A. A. S. conducted the study. All authors were involved in analysing and interpreting the data, as well as drafting and reviewing the manuscript. All authors approved the final draft of the manuscript for submission.</p></sec></ack><ref-list id="dom13134-bibl-0001" content-type="cited-references"><title>REFERENCES</title><ref id="dom13134-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="dom13134-cit-0002">
<string-name>
<surname>Wang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Geiss</surname>
<given-names>LS</given-names>
</string-name>, <string-name>
<surname>Williams</surname>
<given-names>DE</given-names>
</string-name>, <string-name>
<surname>Gregg</surname>
<given-names>EW</given-names>
</string-name>. <article-title>Trends in emergency department visit rates for hypoglycaemia and hyperglycaemic crisis among adults with diabetes, United States, 2006&#x02013;2011</article-title>. <source>PLoS One</source>. <year>2015</year>;<volume>10</volume>:<fpage>e0134917</fpage>.<pub-id pub-id-type="pmid">26252486</pub-id></mixed-citation></ref><ref id="dom13134-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="dom13134-cit-0003">
<string-name>
<surname>Weinstock</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Xing</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Maahs</surname>
<given-names>DM</given-names>
</string-name>, et al. <article-title>Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D exchange clinic registry</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2013</year>;<volume>98</volume>:<fpage>3411</fpage>&#x02013;<lpage>3419</lpage>.<pub-id pub-id-type="pmid">23760624</pub-id></mixed-citation></ref><ref id="dom13134-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="dom13134-cit-0004">
<string-name>
<surname>Wild</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>von Maltzahn</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Brohan</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Christensen</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Clauson</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Gonder&#x02010;Frederick</surname>
<given-names>L</given-names>
</string-name>. <article-title>A critical review of the literature on fear of hypoglycemia in diabetes: implications for diabetes management and patient education</article-title>. <source>Patient Educ Couns</source>. <year>2007</year>;<volume>68</volume>:<fpage>10</fpage>&#x02013;<lpage>15</lpage>.<pub-id pub-id-type="pmid">17582726</pub-id></mixed-citation></ref><ref id="dom13134-bib-0004"><label>4</label><mixed-citation publication-type="book" id="dom13134-cit-0005">
<string-name>
<surname>Cryer</surname>
<given-names>P</given-names>
</string-name>. <source>Hypoglycemia in Diabetes: Pathophysiology, Prevalence and Prevention</source>. <publisher-loc>Alexandria, VA</publisher-loc>: <publisher-name>American Diabetes Association</publisher-name>; <year>2012</year>.</mixed-citation></ref><ref id="dom13134-bib-0005"><label>5</label><mixed-citation publication-type="miscellaneous" id="dom13134-cit-0006">Eli Lilly and Company. Information for the user: glucagon for injection (rDNA origin). <year>2012</year>
<ext-link ext-link-type="uri" xlink:href="http://pi.lilly.com/us/rglucagon-ppi.pdf">http://pi.lilly.com/us/rglucagon-ppi.pdf</ext-link>. Accessed November 3, 2016.</mixed-citation></ref><ref id="dom13134-bib-0006"><label>6</label><mixed-citation publication-type="miscellaneous" id="dom13134-cit-0007">
<collab collab-type="authors">GlucaGen(r) Hypokit(r)</collab>
. Instructions for use. <year>2016</year>
<ext-link ext-link-type="uri" xlink:href="http://www.glucagenhypokit.com/instructions.html">http://www.glucagenhypokit.com/instructions.html</ext-link>. Accessed November 3, 2016.</mixed-citation></ref><ref id="dom13134-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="dom13134-cit-0008">
<string-name>
<surname>Pontiroli</surname>
<given-names>AE</given-names>
</string-name>. <article-title>Intranasal glucagon: a promising approach for treatment of severe hypoglycemia</article-title>. <source>J Diabetes Sci Technol</source>. <year>2015</year>;<volume>9</volume>:<fpage>38</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="pmid">25385946</pub-id></mixed-citation></ref><ref id="dom13134-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="dom13134-cit-0009">
<string-name>
<surname>Dash</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Xiao</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Stahel</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Koulajian</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Giacca</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lewis</surname>
<given-names>GF</given-names>
</string-name>. <article-title>Evaluation of the specific effects of intranasal glucagon on circulating glucose and lipid concentrations in healthy males during a pancreatic clamp</article-title>. <source>Diabetes Obes Metab</source>. <year>2018</year>;20:328&#x02013;334.</mixed-citation></ref><ref id="dom13134-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="dom13134-cit-0010">
<string-name>
<surname>Yale</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Dulude</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Egeth</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Faster use and fewer failures with needle&#x02010;free nasal glucagon vs injectable glucagon in severe hypoglycemia rescue: a simulation study</article-title>. <source>Diabetes Tech Ther</source>. <year>2017</year>;<volume>19</volume>:<fpage>423</fpage>&#x02013;<lpage>432</lpage>.</mixed-citation></ref><ref id="dom13134-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="dom13134-cit-0011">
<string-name>
<surname>Pires</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Fortuna</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Alves</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Falc&#x000e3;o</surname>
<given-names>A</given-names>
</string-name>. <article-title>Intranasal drug delivery: how, why and what for?</article-title>
<source>J Pharm Pharm Sci</source>. <year>2009</year>;<volume>12</volume>:<fpage>288</fpage>&#x02013;<lpage>311</lpage>.<pub-id pub-id-type="pmid">20067706</pub-id></mixed-citation></ref><ref id="dom13134-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="dom13134-cit-0012">
<string-name>
<surname>Perelman</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fisher</surname>
<given-names>AN</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Knight</surname>
<given-names>A</given-names>
</string-name>. <article-title>Impact of allergic rhinitis and its treatment on the pharmacokinetics of nasally administered fentanyl</article-title>. <source>Int J Clin Pharmacol Ther</source>. <year>2013</year>;<volume>51</volume>:<fpage>349</fpage>&#x02013;<lpage>356</lpage>.<pub-id pub-id-type="pmid">23458227</pub-id></mixed-citation></ref><ref id="dom13134-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="dom13134-cit-0013">
<string-name>
<surname>Krieter</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Chiang</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Gyaw</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Pharmacokinetic properties and human use characteristics of an FDA&#x02010;approved intranasal naloxone product for the treatment of opiod overdose</article-title>. <source>J Clin Pharmacol</source>. <year>2016</year>;<volume>56</volume>:<fpage>1243</fpage>&#x02013;<lpage>1253</lpage>.<pub-id pub-id-type="pmid">27145977</pub-id></mixed-citation></ref><ref id="dom13134-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="dom13134-cit-0014">
<string-name>
<surname>Illum</surname>
<given-names>L</given-names>
</string-name>. <article-title>Nasal drug delivery &#x02010; possibilities, problems and solutions</article-title>. <source>J Control Release</source>. <year>2003</year>;<volume>87</volume>:<fpage>187</fpage>&#x02013;<lpage>198</lpage>.<pub-id pub-id-type="pmid">12618035</pub-id></mixed-citation></ref><ref id="dom13134-bib-0014"><label>14</label><mixed-citation publication-type="book" id="dom13134-cit-0015">
<string-name>
<surname>Marx</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Williams</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Birkhoff</surname>
<given-names>M</given-names>
</string-name>. In: <person-group person-group-type="editor"><name><surname>Vallisuta</surname><given-names>O</given-names></name></person-group>, ed. <source>Intranasal Drug Administration &#x02014; An Attractive Delivery Route for some Drugs, Drug Discovery and Development &#x02010; from Molecules to Medicine</source>. <publisher-name>InTech</publisher-name>; <year>2015</year>
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5772/59468">https://doi.org/10.5772/59468</ext-link>. <ext-link ext-link-type="uri" xlink:href="https://www.intechopen.com/books/drug-discovery-and-development-from-molecules-to-medicine/intranasal-drug-administration-an-attractive-delivery-route-for-some-drugs">https://www.intechopen.com/books/drug&#x02010;discovery&#x02010;and&#x02010;development&#x02010;from&#x02010;molecules&#x02010;to&#x02010;medicine/intranasal&#x02010;drug&#x02010;administration&#x02010;an&#x02010;attractive&#x02010;delivery&#x02010;route&#x02010;for&#x02010;some&#x02010;drugs</ext-link>. Accessed November 3, 2016.</mixed-citation></ref><ref id="dom13134-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="dom13134-cit-0016">
<string-name>
<surname>Reno</surname>
<given-names>FE</given-names>
</string-name>, <string-name>
<surname>Normand</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>McInally</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>A novel nasal powder formulation of glucagon: toxicology studies in animal models</article-title>. <source>BMC Pharmacol Toxicol</source>. <year>2015</year>;<volume>16</volume>:<fpage>29</fpage>.<pub-id pub-id-type="pmid">26502880</pub-id></mixed-citation></ref><ref id="dom13134-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="dom13134-cit-0017">
<string-name>
<surname>Sherr</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Ruedy</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Foster</surname>
<given-names>NC</given-names>
</string-name>, et al. <article-title>Glucagon nasal powder: a promising alternative to intramuscular glucagon in youth with type 1 diabetes</article-title>. <source>Diabetes Care</source>. <year>2016</year>;<volume>39</volume>:<fpage>555</fpage>&#x02013;<lpage>562</lpage>.<pub-id pub-id-type="pmid">26884472</pub-id></mixed-citation></ref><ref id="dom13134-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="dom13134-cit-0018">
<string-name>
<surname>Rickels</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Ruedy</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Foster</surname>
<given-names>NC</given-names>
</string-name>, et al. <article-title>Intranasal glucagon for treatment of insulin&#x02010;induced hypoglycemia in adults with type 1 diabetes: a randomized crossover noninferiority study</article-title>. <source>Diabetes Care</source>. <year>2016</year>;<volume>39</volume>:<fpage>264</fpage>&#x02013;<lpage>270</lpage>.<pub-id pub-id-type="pmid">26681725</pub-id></mixed-citation></ref><ref id="dom13134-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="dom13134-cit-0019">
<string-name>
<surname>Deeb</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Dulude</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Nasal glucagon (NG) for the treatment of moderate to severe hypoglycemia (hypo) episodes in children and adolescents with type 1 diabetes (T1D) in home or school settings</article-title>. <source>Pediatr Diabetes</source>. <year>2016</year>;<volume>17</volume>:<fpage>85</fpage>.</mixed-citation></ref><ref id="dom13134-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="dom13134-cit-0020">
<string-name>
<surname>Seaquist</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Dulude</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Nasal glucagon for the treatment of moderate&#x02010;to&#x02010;severe hypoglycemic episodes in real&#x02010;world settings in adults with type 1 diabetes</article-title>. <source>Diabetes</source>. <year>2017</year>;66:A94.</mixed-citation></ref><ref id="dom13134-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="dom13134-cit-0021">
<string-name>
<surname>Blaiss</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Dicpinigaitis</surname>
<given-names>PV</given-names>
</string-name>, <string-name>
<surname>Eccles</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Wingertzahn</surname>
<given-names>MA</given-names>
</string-name>. <article-title>Consumer attitudes on cough and cold: US (ACHOO) survey results</article-title>. <source>Curr Med Res Opin</source>. <year>2015</year>;<volume>31</volume>:<fpage>1527</fpage>&#x02013;<lpage>1538</lpage>.<pub-id pub-id-type="pmid">25535904</pub-id></mixed-citation></ref><ref id="dom13134-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="dom13134-cit-0022">
<string-name>
<surname>Djupesland</surname>
<given-names>PG</given-names>
</string-name>. <article-title>Nasal drug delivery devices: characteristics and performance in a clinical perspective&#x02014;a review</article-title>. <source>Drug Deliv Transl Res</source>. <year>2013</year>;<volume>3</volume>:<fpage>42</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">23316447</pub-id></mixed-citation></ref><ref id="dom13134-bib-0022"><label>22</label><mixed-citation publication-type="miscellaneous" id="dom13134-cit-0023">Cerner Multim, Inc. Oxymetazoline nasal disease interactions. <ext-link ext-link-type="uri" xlink:href="https://www.drugs.com/disease-interactions/oxymetazoline-nasal.html">https://www.drugs.com/disease&#x02010;interactions/oxymetazoline&#x02010;nasal.html</ext-link>. 2017. Accessed June 27, 2017.</mixed-citation></ref><ref id="dom13134-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="dom13134-cit-0024">
<string-name>
<surname>Jackson</surname>
<given-names>GG</given-names>
</string-name>, <string-name>
<surname>Dowling</surname>
<given-names>HF</given-names>
</string-name>, <collab collab-type="authors">Anderson TO</collab>
, <string-name>
<surname>Riff</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Saporta</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Turck</surname>
<given-names>M</given-names>
</string-name>. <article-title>Susceptibility and immunity to common upper respiratory viral infections&#x02010;&#x02010;the common cold</article-title>. <source>Ann Intern Med</source>. <year>1960</year>;<volume>53</volume>:<fpage>719</fpage>&#x02013;<lpage>738</lpage>.<pub-id pub-id-type="pmid">13718486</pub-id></mixed-citation></ref><ref id="dom13134-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="dom13134-cit-0025">
<string-name>
<surname>Kim</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Sussman</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>H&#x000e9;bert</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lumry</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Lutsky</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Gates</surname>
<given-names>D</given-names>
</string-name>. <article-title>Desloratadine therapy for symptoms associated with perennial allergic rhinitis</article-title>. <source>Ann Allergy Asthma Immunol</source>. <year>2006</year>;<volume>96</volume>:<fpage>460</fpage>&#x02013;<lpage>465</lpage>.<pub-id pub-id-type="pmid">16597081</pub-id></mixed-citation></ref><ref id="dom13134-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="dom13134-cit-0026">
<string-name>
<surname>Simons</surname>
<given-names>FE</given-names>
</string-name>, <string-name>
<surname>Prenner</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Finn</surname>
<given-names>A</given-names>
<suffix>Jr</suffix>
</string-name>; Desloratadine Study Group<article-title>Efficacy and safety of desloratidine in the treatment of perennial allergic rhinitis</article-title>. <source>J Allergy Clin Immunol</source>. <year>2003</year>;<volume>111</volume>:<fpage>617</fpage>&#x02013;<lpage>622</lpage>.<pub-id pub-id-type="pmid">12642846</pub-id></mixed-citation></ref><ref id="dom13134-bib-0026"><label>26</label><mixed-citation publication-type="miscellaneous" id="dom13134-cit-0027">Cerner Multum, Inc. Oxymetazoline solution. <ext-link ext-link-type="uri" xlink:href="https://www.drugs.com/cdi/oxymetazoline-solution.html">https://www.drugs.com/cdi/oxymetazoline-solution.html</ext-link>. 2017. Accessed June 27, 2017.</mixed-citation></ref><ref id="dom13134-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="dom13134-cit-0028">
<string-name>
<surname>Blauw</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Wendl</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>DeVries</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Heise</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Jax</surname>
<given-names>T</given-names>
</string-name>. <article-title>Pharmacokinetics and pharmacodynamics of various glucagon dosages at different blood glucose levels</article-title>. <source>Diabetes Obes Metab</source>. <year>2016</year>;<volume>18</volume>:<fpage>34</fpage>&#x02013;<lpage>39</lpage>.</mixed-citation></ref><ref id="dom13134-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="dom13134-cit-0029">
<string-name>
<surname>Dulude</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Sicard</surname>
<given-names>&#x000c9;</given-names>
</string-name>, <string-name>
<surname>Rufiange</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Pharmacokinetics (PK), Pharmacodynamics (PD), and safety following single or repeated 3 mg doses of nasal glucagon (NG) in adults with type 1 or type 2 diabetes (T1D or T2D)</article-title>. <source>Pediatr Diabetes</source>. <year>2016</year>;<volume>17</volume>:<fpage>85</fpage>.</mixed-citation></ref></ref-list></back></article>